Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, Riveros C, Davidson M, Graña C, Bonnet H, Jarde A, Ávila C, Nejstgaard CH, Menon S, Ferrand G, Kapp P, Breuer C, Schmucker C, Sguassero Y, Nguyen TV, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, Chaimani A, Boutron I.
Ghosn L, et al. Among authors: nguyen tv.
Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013881. doi: 10.1002/14651858.CD013881.pub2.
Cochrane Database Syst Rev. 2023.
PMID: 37260086
Review.
AUTHORS' CONCLUSIONS: In hospitalized people with COVID-19, results show a beneficial effect of tocilizumab on all-cause mortality in the short term and probably little or no difference in the risk of adverse events compared to standard care alone or placebo. ...
AUTHORS' CONCLUSIONS: In hospitalized people with COVID-19, results show a beneficial effect of tocilizumab on all-cause mortality in the sh …